Vertex Pharmaceuticals signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a triple combination therapy for cystic fibrosis (CF). The agreement aims to improve access to the treatment for approximately 3,800 eligible patients across Canada, including up to 60 individuals receiving a medicine that treats the underlying cause of their disease for the first time. This LOI follows positive reimbursement recommendations issued by Canada's Drug Agency (CDA-AMC) in December 2025 and Institut national d'excellence en santé et services sociaux (INESSS) in April 2026.

Agreement Details

The LOI marks a step toward public listing of ALYFTREK through publicly funded drug programs. Vertex will now initiate discussions with provinces and territories to finalize the process. The therapy is designed for patients aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Therapy Overview

ALYFTREK combines vanzacaftor, tezacaftor, and deutivacaftor to address the defective CFTR protein. Vanzacaftor and tezacaftor facilitate the processing and trafficking of the CFTR protein to the cell surface, while deutivacaftor acts as a potentiator to improve salt and water flow across the cell membrane. The therapy is approved in the United States, United Kingdom, European Union, Canada, New Zealand, Switzerland, and Australia.

Safety Considerations

Elevated transaminases have been observed in some patients treated with ALYFTREK. Cases of liver failure leading to transplantation and death have been reported in patients taking a fixed-dose combination drug containing tezacaftor and ivacaftor, which shares active ingredients with ALYFTREK. Liver injury has primarily been reported within the first six months of treatment initiation.

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) approved an expanded label for CASGEVY (exagamglogene autotemcel) for patients aged 2 years and older with sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). This approval makes CASGEVY the first and only approved genetic therapy indicated for children as young as 2 years for both SCD and TDT. Approximately 5,500 additional children in the U.S. are now eligible for this one-time therapy, which was previously approved for people 12 years and older.

The approval decision was granted 53 days after filing and was the eighth approval selected for the Commissioner’s National Priority Voucher (CNPV) pilot program. Vertex has established a network of independently operated, authorized treatment centers (ATCs) throughout the U.S., with more than 75 activated ATCs currently available to offer CASGEVY to eligible patients.

Clinical Trial Data and Mechanism

CASGEVY is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy consisting of the patient’s own hematopoietic stem and progenitor cells, administered as a one-time single dose for intravenous infusion. The cells are edited at the erythroid specific enhancer region of the BCL11A gene, resulting in the production of high levels of fetal hemoglobin (HbF). In patients with severe SCD, this prevents red blood cells from forming abnormal sickle shapes. In patients with TDT, it increases HbF and total hemoglobin levels, eliminating dependence on regular red blood cell transfusions.

The safety and effectiveness in patients aged 5 years to less than 12 years with SCD were evaluated in a clinical trial of 11 patients. All eight evaluable patients achieved the primary efficacy outcome of VF12, defined as no protocol-defined severe VOCs for at least 12 consecutive months within the first 24 months after infusion. For TDT, a trial of 15 patients aged 5 to less than 12 years showed that eight of nine evaluable patients achieved transfusion independence for 12 consecutive months, with a median duration of 20.1 months. Extrapolation to the younger pediatric age population was granted to expand the indication to 2 years of age and above for both conditions.

Adverse Reactions and Regulatory Status

The most common Grade 3 or 4 non-laboratory adverse reactions were mucositis and febrile neutropenia in patients with SCD and TDT, and decreased appetite in patients with SCD. Warnings include neutrophil engraftment failure, delayed platelet engraftment, hypersensitivity reactions, and off-target genome editing risk. Full myeloablative conditioning is administered prior to treatment with CASGEVY. Regulatory review for label expansion is currently underway in the Kingdom of Saudi Arabia and the United Kingdom.

In June, the FDA accepted Vertex’s Biologics License Application submission for povetacicept in adults with immunoglobulin A nephropathy. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026. If approved, povetacicept will become the first commercialized therapy in Vertex’s emerging nephrology franchise.